Non-Small Cell Lung Cancer - Metastatic

IRB#9059 Lung Cancer Mutation Consortium

1st line

IRB# 11851 GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or Atezolizumab In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

IRB# 11845 GO29431: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) Compared with a Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine for PD-L1-Selected Chemotherapy Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

2nd/3rd Line

IRB#11740 Tiger 3: Rociletinib Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR

IRB#11046 Lung-MAP: Study involving multiple drugs

Correlatives

http://www.ohsu.edu/research/nda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

3/6/2017